A director at Hanmi Pharmaceutical Co Ltd bought 370 shares at 254,000.000KRW and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
HANMI PHARMACEUTICAL (KR), a company active in the Biotechnology industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date December 10, 2021, the closing price was KRW 280,500.00 and i...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
We upgrade our rating from Marketperform to BUY in light of the potential milestone payments from global pharmas over its out-licensed pipeline drugs in the mid to long term and above-average growth in outpatient prescriptions. - We raised the PSR applied to the current operating value to better recognize the rapidly growing sales of new drugs and revise up our target price to KRW670,000 as we upwardly adjusted the success rates of key pipeline drugs and a potential expansion of drug indic...
SEOUL, South Korea & BEIJING--(BUSINESS WIRE)-- Hanmi Pharmaceutical Co. Ltd (Hanmi) (KRX:128940), a Korea-based pharmaceutical company, and Innovent Biologics (Suzhou) Co. Ltd (Innovent), a China based biopharmaceutical company, today announced a strategic partnership to co-develop and co-commercialize a novel immuno-oncology bispecific antibody on a global basis. The bispecific antibody constructed using contributions from both Hanmi and Innovent enables immunotherapy and targeted therapy at the same time. This molec...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
SEOUL, South Korea--(BUSINESS WIRE)-- Hanmi Pharmaceutical Co. Ltd (Hanmi)(KRX:128940), a Korea-based pharmaceutical company, today announced that it has entered into an exclusive development and license agreement with Genentech, a member of the Roche Group, for the development and commercialization of Hanmi’s pan-RAF inhibitor, HM95573 which is currently in Phase I clinical development. Under the terms of the agreement, Genentech will obtain exclusive worldwide rights, except South Korea, to develop and commerc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.